Drug developer to report quarterly to department -- Department to submit annual report to LRC

submit annual report to LRC. (1) The drug developer shall quarterly prepare and submit to the department a: (a) Report on the progress of any multistate drug development clinical trials with ibogaine conducted pursuant to KRS 218A.511 to 218A.519; and (b) Financial status report, including information to verify expenditures of Commonwealth funds and required matching funds. (2) The department shall submit an annual report by December 1 each year to the Legislative Research Commission for referral to the Interim Joint Committee on Health Services on the progress of the drug development clinical trials and their related financial status until the clinical trials are concluded.